On 05-06 March 2021, the European Behavioural Pharmacology Society (EBPS) and the Canadian Biomarker Integration Network for Depression (CAN-BIND) launched…
Read More
Hippocampal Tail Volume as a Predictive Biomarker of Antidepressant Treatment
Author: Dr. Nikita NogovitsynEditors: Dr. Sagar Parikh and Dr. Wegdan Rashad Background Imagine you wanted to predict which athlete might…
Read More
Episode 02: Ketamine Vs ECT for Resistant Depression
This podcast episode explores the CAN-BIND study on ketamine vs ECT for treatment-resistant depression. Featuring our study participant, Sophie.
Read More
Webinar: Mental Health and Addiction in the Wake of COVID-19
Forthlane Partners hosted a webinar on Friday 8 May, 2020 that discussed the impact of social changes during COVID-19 on…
Read More
CAN-BIND Article Featured on Nature Communications Editor’s Highlights
Congratulations to the CAN-BIND team on being featured on the Nature Communications Editor’s Highlights page: From Brain to Behaviour in…
Read More
Researcher Spotlight: Dr. Kate Harkness
Statistics Canada reports that 33% of Canadians experience some sort of childhood maltreatment before the age of 15, which can…
Read More
CAN-BIND Annual Workshop 2019 (Agenda)
Message from Dr. Sidney Kennedy (Newsletter Issue 6)
The CAN-BIND program is at an exciting stage in its clinical research progress. Six of our 13 ongoing studies have…
Read More
Recent Publications (Newsletter Issue 6)
Publications related to CAN-BIND clinical research (published July to October 2018): Early change in reward and punishment sensitivity as a…
Read More
Brain Scans: More than Black and White
Six CAN-BIND Community Advisory Committee (CAC) teleconference meetings are held each year. During these sessions, a CAN-BIND research scientist is…
Read More
